Related Experiment Video
Updated: Jun 5, 2026
07:20
Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Bisphosphonates for post-menopausal osteoporosis: are they all the same?
1Faculty of Medicine of Geneva, Division of Bone Diseases, Department of Rehabilitation and Geriatrics, University Hospitals, CH_1211 Geneva 14, Switzerland. Rene.Rizzoli@unige.ch
QJM : Monthly Journal of the Association of Physicians
|January 25, 2011
Summary
Choosing the right bisphosphonate for post-menopausal osteoporosis (PMO) involves balancing fracture risk reduction, safety, and patient preference. This review compares key bisphosphonates, highlighting differences in efficacy and side effects to guide clinical decisions.
Area of Science:
- Pharmacology and Clinical Efficacy of Bisphosphonates
- Osteoporosis Treatment and Fracture Prevention
Background:
- Post-menopausal osteoporosis (PMO) treatment prioritizes fracture risk reduction.
- Bisphosphonates are established first-line therapies for osteoporosis with proven anti-fracture efficacy.
- Clinical decision-making among various bisphosphonates presents challenges due to differing characteristics.
Purpose of the Study:
- To review the pharmacology of different bisphosphonates.
- To discuss how pharmacological properties influence bisphosphonate efficacy.
- To summarize clinical safety and efficacy data for bisphosphonates in PMO.
Main Methods:
- Review of clinical trial data on bisphosphonates for PMO.
- Analysis of expert body opinions on bisphosphonate therapy.
- Synthesis of pharmacological characteristics, safety profiles, and efficacy data.
Main Results:
- Alendronate, risedronate, ibandronate, and zoledronic acid reduce vertebral fractures in PMO.
- Zoledronic acid and risedronate show significant non-vertebral fracture risk reduction; alendronate, risedronate, and zoledronic acid reduce hip fracture risk.
- Ibandronate and zoledronic acid demonstrate the most persistent anti-fracture effects; side effects include GI issues (oral) and acute phase reactions (IV).
Conclusions:
- Selection of bisphosphonates for PMO requires consideration of efficacy, safety, cost-effectiveness, and patient preference.
- Differences in fracture risk reduction (vertebral, non-vertebral, hip) exist among bisphosphonates.
- Understanding pharmacological profiles and side effect associations is crucial for optimal patient management.
Related Concept Videos
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:31Essential Minerals for Bone Health
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...